Introduction
Cardiac surgery-associated acute kidney injury (AKI) is a common complication after cardiac surgery and has an established link with increased mortality [1] [2] [3] [4] [5] and medical costs [6] . In a recent study, AKI associated with a decreased estimated glomerular filtration rate (eGFR) (N25%, N50%, and N75%) within 1 week of surgery, respectively, has been reported to occur in 24% (n = 829), 7% (n = 228), and 3% (n = 119) of cardiac surgery patients (n = 3500), and was an independent predictor of death [1] . The pathogenesis of cardiac surgery-associated AKI is thought to be mediated by a reduction in renal blood flow induced by wide-ranging factors such as exogenous and endogenous toxins, metabolic abnormalities, ischemia and reperfusion injury, neurohormonal activation, proinflammatory and vasoconstrictive mediators, and oxidative stress [2] [3] [4] [5] . Surgical procedures and cardiopulmonary bypass (CPB) activate inflammatory mediators, adhesion molecules, and proinflammatory transcription factors, leading to cellular injury and AKI [2] . Perioperative low cardiac output is directly related to AKI risk due to hyperactivity of sympathetic nervous system components such as the renin-angiotensinaldosterone system, which increases renal vasoconstriction [3] .
Atrial natriuretic peptide (ANP) is a potent endogenous natriuretic, diuretic, and vasorelaxant peptide with an important role in regulating blood pressure and fluid homeostasis [7] . It raises the pressure within the glomerular capillaries by dilating afferent renal arterioles and constricting efferent arterioles [8] , resulting in increased glomerular filtration and urine output. Atrial natriuretic peptide increases medullary vasa recta blood flow [9] and, by doing so, may protect against medullary ischemia. Atrial natriuretic peptide also preserves glomerular filtration rate (GFR) and reduces renal tissue damage in rat models of acute ischemic renal failure [10] . It confers anti-inflammatory effects by inhibiting nuclear factor (NF) κB activation and cytokine production [11] [12] [13] . In recent studies by our group using a rat model of renal ischemia-reperfusion injury, pretreatment and posttreatment with ANP attenuated the messenger RNA expression of proinflammatory cytokines in kidney and lung by inhibiting NF-κB [14, 15] .
Review articles have shown that ANP infusion induces a diuretic effect with increased creatinine clearance, preserves postoperative renal function, reduces the usage of conventional diuretics, and suppresses the renin-angiotensin-aldosterone system in higher-risk patients after cardiac surgery [16, 17] . Two randomized controlled trials (RCTs) in a clinical setting have demonstrated that low-dose ANP infusion improves renal function in patients undergoing coronary artery bypass grafting (CABG) with left ventricular dysfunction [18] and chronic kidney disease [19] . Until now, however, no earlier multicenter RCTs have investigated the effects of ANP infusion in patients with cardiac surgery-associated AKI. We therefore decided to evaluate the effects of ANP on renal function and medical costs in patients with cardiac surgery-associated AKI.
Materials and methods

Study design and patients
The Japanese trial for AKI in Post-cardiovascular surgery patients by ANP (JAPAN) was a prospective, multicenter, randomized, double-blind, placebo-controlled study in patients with AKI after cardiovascular surgery. Patients were enrolled at 11 hospitals in Japan from May 2012 through March 2015 and were followed up for 90 days after enrollment. This study protocol was approved by the ethics committee at each participating institution, starting with Tokyo Medical and Dental University, the coordinating center. This study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Informed written consent was obtained from all patients. This study was registered with the University Hospital Medical Information Network (UMIN 000006812). Study coordinators at each hospital registered data into the Internet Data and Information Center for Medical Research (INDICE). Patients were assigned by the INDICE randomization system to receive either ANP or placebo. A flowchart of the study design and patient selection is shown in Fig. 1 . Inclusion criteria were a patient age of ≥20 years and recent elective cardiac surgery, namely, CABG, valve surgery, thoracic aortic aneurysm surgery, or a combination thereof. The definition of AKI was based on the Kidney Disease: Improving Global Outcomes (KDIGO) criteria: an increase in serum creatinine of at least 0.3 mg/dL from the preoperative level within 48 hours after cardiac surgery [20] . The exclusion criteria were (1) severe hypotension or cardiogenic shock; (2) right ventricular infarction; (3) dehydration; (4) end-stage renal disease; (5) administration of nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme (ACE) inhibitor, or angiotensin receptor blocker (ARB) within 24 hours before the operation; (6) administration of contrast agent within 3 days before the operation; and (7) extracorporeal membrane oxygenation.
The patients were randomly assigned to receive a low-dose of ANP (carperitide; Daiichi-Sankyo Pharmaceutical, Tokyo, Japan) at the rate of 0.02 μg kg −1 min −1 (2 mL/h) or placebo (5% glucose, 2 mL/h) by the INDICE randomization system. The infusion of ANP or placebo continued until the serum creatinine level fell back to the preoperative level. The primary end point was a change in renal function over the 90-day follow-up measured by serum levels of creatinine and cystatin C, and creatinine clearance or eGFR. The secondary end points were (1) a need for renal replacement therapy over the 90-day follow-up, (2) the lengths of intensive care unit (ICU) and hospital stays, and (3) medical costs incurred over the 90-day follow-up. Renal replacement therapy was started if patients with AKI met at least one of the following criteria: oliguria (urine output b100 mL in a 6-hour period) unresponsive to fluid resuscitation measures, a serum potassium level higher than 6.5 mmol/L, severe acidemia (pH b7.2), serum urea nitrogen level higher than 70 mg/dL, serum creatinine level higher than 3.4 mg/dL, or the presence of clinically significant organ edema [21] . The diagnostic procedure combination/per-diem payment system was used to calculate total medical costs. Medical costs under diagnostic procedure combination/per-diem payment system consist of inclusive costs and fee-for-service. The inclusive component (D file) covers charges for hospitalization, examinations, and medication, and has a flat-rate per-diem fee based on diagnostic categories. The fee-forservice component (E file) reimburses costs for expensive procedure such as surgeries and renal replacement therapy. Total medical costs (¥) were calculated as 10 × (D file + E file).
Hemodynamics and arrhythmias were recorded during the study period in the ICU. The definition criteria for arrhythmias are atrial fibrillation, atrial flutter, supraventricular tachycardia, premature ventricular contraction, ventricular tachycardia, or ventricular fibrillation.
Sample size and power calculation
The results from Sezai et al [19] were used to calculate the sample size for this study. A sample size of 87 for each group is estimated to have 80% power to detect a difference in means of 74.25, assuming that the common SD is 196 using a 2-group t test with a .05 1-sided significance level. We estimated 194 as the sample size against the loss of about 10% as a dropout rate. Finally, a sample size of 200 was detected as sufficient for this study.
Statistical analysis
Qualitative data are shown as numbers (percentages) and quantitative data are shown as medians (interquartile ranges). The assessor was blinded for the treatment groups. Although we tried repeated-measures analysis of variance, it was significant for interaction effect between time and variables. Therefore, we could not do repeated-measures analysis of variance. Data were analyzed by the Mann-Whitney U test to analyze each pairing of groups. Contingency tables on medical histories and surgical procedures were done by Fisher exact test instead of the χ 2 test. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a Fig. 1 . Flowchart of study design and patient selection for a prospective randomized placebo-controlled study. ESRD indicates end-stage renal disease.
graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). More precisely, EZR is a modified version of R commander designed to add statistical functions frequently used in biostatistics. A P value less than .05 was considered statistically significant.
Results
Although we planned to enroll 200 patients and prolonged the study period for an additional 1 year (May 2012-March 2015), we were unable to reach 200 patients and actually randomized 77 (Fig. 1) . Reasons why we were only able to randomize 77 patients included multiple and major delays in approval of ethics committees, difficulty in obtaining consent from patients, and decisions by several hospitals to prioritize patients with ventricular assist devices. Furthermore, many surgeons in trial sites insisted on using ANP in patients with high preoperative creatinine levels despite the ongoing trial and lack of evidence. Thus, these patients were excluded before assessment for eligibility and were administered ANP during surgery. Consequently, there were 115 patients who met increase in serum creatinine at least 0.3 mg/dL within 48 hours after cardiac surgery and had not been exposed to ANP. However, 38 patients were excluded because of other exclusion criteria (severe hypotension, cardiogenic shock, end-stage renal disease, or preoperative medication within 24 hours), later decision by the surgeon, and refusal of consent. Therefore, total number of potential recruits (number of cardiac surgery patients in 3 years in the 11 centers who had a ≥0.30 mg/dL increase in creatinine but were not randomized) was 38. Of the 77 randomized patients, 37 were assigned to the ANP group and 40 were assigned to the placebo group. Thirty-four patients in the ANP group and 37 patients in the placebo group were in AKI stage 1, and 3 patients in the ANP group and 3 patients in the placebo group were in AKI stage 2 at the time of enrollment. The 2 groups were similar with regard to baseline characteristics (Table 1 ) and operative details (Table 2 ). With the exception of 2 patients who underwent off-pump CABG in the placebo group, all of the patients underwent cardiovascular surgery by CPB.
The primary end point, a change in renal function such as serum levels of creatinine and cystatin C, creatinine clearance or eGFR, did not significantly differ between the 2 groups (Table 3 ). However, ANP infusion significantly (P = .018) increased the urine output on day 1 compared with placebo. Table 4 shows the postoperative details on the AKI patients after cardiac surgery. At the time of the AKI diagnosis, the median dose of furosemide was significantly higher in the ANP group (25 mg) than in the placebo group (10 mg; P = .036). On days 2 and 3, however, the furosemide doses were significantly higher in the placebo group (70 and 98 mg, respectively) than in the ANP group (20 and 25 mg; P = .03 and .004, respectively; Table 4 ). Regarding AKI stage at 90 days, 1 patient in the ANP group and 4 patients in the placebo group were in AKI stage 2, and 2 patients in the ANP group were in AKI stage 1.
Significant differences between the 2 groups were also absent in the secondary end points, namely, the need for renal replacement therapy, the lengths of ICU and hospital stays, and medical costs (Table 4) . One patient in the ANP group and 3 patients in the placebo group required renal replacement therapy during the early postoperative period. There were no significant differences in arrhythmia or the number of days of mechanical ventilation. Qualitative data are shown as numbers (percentages); quantitative data are shown as medians (interquartile ranges). CCB indicates calcium-channel blocker. Adverse events in the ANP group included hypotension in 2 patients and arrhythmia in 14. Adverse events in the placebo group included hypotension in 4 patients, arrhythmia in 15, stroke in 1, and sepsis in 1. Two patients in the ANP group and 3 patients in the placebo group died within the 90-day follow-up.
Discussion
The major finding in the present study was the lack of any significant difference between the groups in the primary end point and changes in renal function. Significant differences between the groups were also absent in the secondary end points, namely, the need for renal replacement therapy, the lengths of ICU and hospital stays, and the medical costs.
Features of the JAPAN study
The design of the present study required the selection of patients at high risk for the development of AKI. We therefore included patients undergoing thoracic aortic aneurysm surgery and valve replacement with or without CABG, along with patients undergoing CABG in association with other interventions. Patients undergoing cardiac surgery are exposed to nephrotoxic drugs. Nonsteroidal anti-inflammatory drug, ACE inhibitor, and ARB have been shown to impair the autoregulation of the GFR and to decrease both the GFR and perfusion pressure [22] . We therefore excluded patients who received nonsteroidal antiinflammatory drugs, ACE inhibitors, or ARB within 24 hours before the surgery or contrast agents within 3 days before the surgery. In previous RCTs, ANP infusion was started at the initiation of CPB [18, 19] . These studies were therefore trials of AKI prevention in cardiac surgery patients. One trial of ANP treatment has shown beneficial effects in patients with cardiogenic shock-associated AKI, but only at a single center [23] . By contrast, our trial excluded patients with severe hypotension and cardiogenic shock, conditions for which ANP is contraindicated according to pharmaceutical company reports, and it was a multiple-center trial of ANP treatment in which the ANP infusion was started at the diagnosis of AKI.
Effects of ANP on renal function
We assessed renal function by measuring the serum levels of creatinine, the serum level of cystatin C, and creatinine clearance or eGFR in both groups. Unfortunately, there were no significant differences in these variables between groups. We assessed AKI using the KDIGO criteria: an increase in serum creatinine level of at least 0.3 mg/dL within 48 hours [20] . Cardiac surgery-associated AKI is induced by an abrupt deterioration in renal function after cardiac surgery. The serum creatinine level may fail to reflect this deterioration in the first 24 to 48 hours, however, because of the hemodilution occurring during CPB [4] . It can therefore be difficult to detect the early phase of AKI solely on the basis of serum creatinine, especially in patients who undergo CPB. Kinetic models also suggest that it may take days to achieve a steady state after a sustained reduction in creatinine clearance, or possibly in patients who start out with high baseline serum creatinine [24] . Thus, the current renal function markers such as increased serum creatinine or eGFR may be inappropriate for the early diagnosis of AKI. The window of opportunity to treat the early stage of AKI might already be closed when ANP is infused at the point of AKI diagnosis based on elevated creatinine levels.
Cystatin C is one of the new biomarkers of AKI. Preoperative serum cystatin C was superior to serum creatinine or creatinine-based eGFR in predicting the risk of AKI after cardiac surgery [25] . When we measured the serum cystatin C level in addition to serum creatinine level as a biomarker for AKI diagnosis in our study, however, we found no significant difference in the serum cystatin C level between the 2 groups over the 90-day follow-up.
Effects of ANP on urine output
The ANP infusion significantly increased the urine output on day 1. This finding demonstrates ANP's effect in elevating urine output by dilating the afferent renal arterioles, constricting the efferent arterioles [8] , and increasing the medullary vasa recta blood flow [9] . The furosemide doses on days 2 and 3 were also significantly lower in the ANP group than in the placebo group. This finding corroborates one of the earlier studies [26] . A RCT found that furosemide weakened the protection against renal dysfunction after the cardiac surgery [27] . A metaanalysis has also shown that furosemide has no association with significant benefits in the prevention and treatment of AKI, and that a high furosemide dose may cause ototoxicity [28] .
Effects of ANP on medical costs
In the present study, there were no significant differences in D file, E file, or total medical costs between the groups. This may be mainly due to no difference in the need for renal replacement therapy or the length Qualitative data are shown as numbers (percentages); quantitative data are shown as medians (interquartile ranges). 1 D file is the inclusive component which covers charges for hospitalization, examination, and medication, and it is represented by scores. 2 E file is the fee-for service component which reimburses costs for expensive procedure such as surgeries and renal replacement therapy, and it is represented by scores.
of ICU and hospital stays between the groups. Although ANP is more expensive than furosemide, these drugs are included in D file which is the inclusive component.
Study limitations
There were several limitations in the present study. First, the sample was too small to detect meaningful differences between the groups. This study had only 77 subjects. A sample size of 77 (37 vs 40) will have 50.6% power (ie, type II error β will be 0.494) to detect a difference in means of 74.25, assuming the common SD in 196 using a 2-group t test with a .05 1-sided significance level. Therefore, this study had very limited power. In a large population of 25 898 cardiac surgery patients, meanwhile, the rate of dialysis and rate of a doubling of serum creatinine were only 1.7% and 4.3%, respectively [29] . It would thus appear that the rates of dialysis and doubling of serum creatinine are fairly low in most patients after cardiac surgery. The serum creatinine level in our study actually rose by more than 2-fold in 3 patients in each group. We therefore surmised that even if the serum creatinine transiently increases by more than 0.3 mg/dL after cardiac surgery, the increase might be less than a doubling and the level might return to the baseline in most patients. Because there were no AKI stage 3 patients in our study, the present study supports the view that even in early AKI, ANP does not have a clear beneficial effect. Second, it may also have been disadvantageous to adopt KDIGO criteria, an increase in serum creatinine of at least 0.3 mg/dL within 48 hours, as the hemodilutional effects of CPB pump priming could have concealed the increase in serum creatinine and hindered the detection of the early-phase signs of AKI such as renal tubular damage. Third, the preoperative serum creatinine levels were fairly low in most of the patients in our study. A preoperative serum creatinine level of at least 1.2 mg/dL is an established risk factor for AKI, and at least 2.1 mg/dL is associated with a 2.5-fold higher risk than 1.2 mg/dL to less than 2.1 mg/dL [30] . Seven patients in our ANP group and 10 patients in our placebo group had preoperative creatinine levels in the range from 1.2 mg/dL to less than 2.1 mg/L, and 1 patient in our ANP group had a level of at least 2.1 mg/dL. This relatively low preoperative renal function risk factor for AKI might have kept us from clearly demonstrating the treatment effects of ANP in patients with cardiac surgery-associated AKI in our study. Fourth, this study is, at best, a feasibility phase IIa study at this time. Because this trial is small scale and shows safety of low-dose ANP, it is uncertain whether ANP has any renoprotective effect on the early phase of AKI in patients with high serum creatinine level. Further large-scale studies are needed to investigate the effects of ANP on the early phase of cardiac surgeryassociated AKI.
Conclusions
Low-dose ANP infusion showed no renoprotective effect or costsaving effect in the treatment of cardiac surgery-associated AKI in this multicenter prospective randomized control study.
